CNR Institutional Research Information System

CERVELLO, MELCHIORRE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.541
NA - Nord America 2.351
EU - Europa 1.175
SA - Sud America 841
AF - Africa 87
Continente sconosciuto - Info sul continente non disponibili 77
OC - Oceania 6
Totale 9.078
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.209
SG - Singapore 1.911
CN - Cina 994
BR - Brasile 680
HK - Hong Kong 544
VN - Vietnam 415
IT - Italia 344
NL - Olanda 264
FR - Francia 253
KR - Corea 178
BD - Bangladesh 148
IN - India 85
GB - Regno Unito 78
JP - Giappone 76
CA - Canada 61
AR - Argentina 59
DE - Germania 47
FI - Finlandia 39
MX - Messico 36
EC - Ecuador 33
IL - Israele 30
ZA - Sudafrica 28
ID - Indonesia 25
ES - Italia 24
TR - Turchia 22
CO - Colombia 20
PL - Polonia 19
RU - Federazione Russa 16
IQ - Iraq 15
KE - Kenya 15
SA - Arabia Saudita 15
CR - Costa Rica 12
JM - Giamaica 11
MA - Marocco 11
PY - Paraguay 11
SE - Svezia 10
VE - Venezuela 10
AT - Austria 9
CL - Cile 9
PK - Pakistan 9
TN - Tunisia 9
UA - Ucraina 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
AZ - Azerbaigian 7
EG - Egitto 7
LV - Lettonia 7
PE - Perù 7
UZ - Uzbekistan 7
LT - Lituania 6
PH - Filippine 6
TW - Taiwan 6
BG - Bulgaria 5
KH - Cambogia 5
KZ - Kazakistan 5
NP - Nepal 5
OM - Oman 5
AU - Australia 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
PT - Portogallo 4
TT - Trinidad e Tobago 4
BE - Belgio 3
BO - Bolivia 3
CI - Costa d'Avorio 3
HU - Ungheria 3
IE - Irlanda 3
JO - Giordania 3
MD - Moldavia 3
NI - Nicaragua 3
PA - Panama 3
PS - Palestinian Territory 3
SD - Sudan 3
SK - Slovacchia (Repubblica Slovacca) 3
BB - Barbados 2
BS - Bahamas 2
BY - Bielorussia 2
CH - Svizzera 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GR - Grecia 2
HN - Honduras 2
KG - Kirghizistan 2
LU - Lussemburgo 2
MM - Myanmar 2
NO - Norvegia 2
RE - Reunion 2
RO - Romania 2
SI - Slovenia 2
TH - Thailandia 2
GD - Grenada 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
HR - Croazia 1
IR - Iran 1
IS - Islanda 1
KW - Kuwait 1
Totale 8.988
Salva come PNG Salva come JPEG
Città #
Singapore 1.130
Santa Clara 755
Hong Kong 539
Hefei 399
San Jose 250
Lauterbourg 206
Seoul 175
Ashburn 169
Beijing 167
Ho Chi Minh City 145
Hanoi 95
Los Angeles 84
Dallas 79
São Paulo 52
Tokyo 49
New York 44
Buffalo 41
Helsinki 28
Palermo 28
Minamishinagawa 24
Haiphong 23
Da Nang 21
Milan 21
Orem 21
Phoenix 20
Wageningen 20
Council Bluffs 19
Mumbai 19
Bengaluru 18
Chennai 18
Rome 18
Frankfurt am Main 17
Rio de Janeiro 17
Brasília 16
Houston 16
Montreal 15
Nairobi 15
Thái Bình 15
Atlanta 14
Brooklyn 14
Johannesburg 14
Manchester 14
Mexico City 14
Belo Horizonte 13
Curitiba 13
Denver 13
Lappeenranta 11
Quito 11
Toronto 11
Warsaw 11
Dhaka 10
Fortaleza 10
Salvador 10
Ankara 9
Goiânia 9
Guayaquil 9
London 9
Naples 9
Newark 9
Portsmouth 9
Stockholm 9
Chicago 8
Elk Grove Village 8
Montevideo 8
Nuremberg 8
Porto Alegre 8
San José 8
Biên Hòa 7
Bologna 7
Cagliari 7
Genoa 7
Manaus 7
Ninh Bình 7
Philadelphia 7
Poplar 7
Potenza 7
Riga 7
Riyadh 7
Amsterdam 6
Baku 6
Bogotá 6
Boston 6
City of London 6
Guangzhou 6
Kingston 6
Lima 6
Madrid 6
Nanjing 6
Recife 6
San Francisco 6
Shanghai 6
Tashkent 6
Baghdad 5
Bauru 5
Boardman 5
Bắc Ninh 5
Campinas 5
Casablanca 5
Cavallino 5
Düsseldorf 5
Totale 5.292
Salva come PNG Salva come JPEG
Nome #
Photoaging of polystyrene-based microplastics amplifies inflammatory response in macrophages 157
The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods 141
The clinical impact of an extra virgin olive oil enriched mediterranean diet on metabolic syndrome: Lights and shadows of a nutraceutical approach 123
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 110
Potential uses of olive oil secoiridoids for the prevention and treatment of cancer: A narrative review of preclinical studies 98
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells 97
New landscapes and horizons in hepatocellular carcinoma therapy. 95
Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation 87
Identification of an LPS-Induced Chemo-Attractive Peptide from Ciona robusta 85
Cationic Solid-lipid nanoparticles as DNA carriers. 82
A BDE-47/estrone mixture modulates macrophage immune responses and miRNA networks, impairs intestinal barrier integrity in vitro, and alters circulating miRNAs and tight junction expression in vivo 81
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells 78
Spatial distribution of collagene TypeI mRNA in Paracentrotus lividus eggs and embryos. 75
Advances in targeting signal transduction pathways. 71
The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH 71
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. 69
The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma 68
Antitumor effects of curcumin and its combination with cisplatin or doxorubicin on hepatic cancer cells: possible relationship to NF-kB activation and IAP gne expression 66
Cancer therapy and treatments during COVID-19 era 66
Cationic solid lipid nanoparticles complexed with genetic material for liver tumor treatment 65
TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors 65
New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells 65
RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma 64
Sex hormones and risk of liver tumor. 64
New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways 63
NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response 63
The novel NF-kB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. 62
COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. 62
Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines 62
Magnetic Nanoparticles tailored with Peptides/Amphiphilic Cyclodextrins assemblies: from Amyloid- detection to theranostic applications. 61
Gene expression profiling of MCF10A breast epithelial cells exposed to IOERT 61
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway 59
Hepatocellular Carcinoma: A Difficult Cancer to Treat 56
Gamma enolase expression as early marker of neuronal differentiation of murine neuroblastoma cells N-115 55
GSK-3 in liver diseases: Friend or foe? 55
Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment 55
Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population 55
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53 54
Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis 54
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells 54
Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression 53
Abilities of ?-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells 53
Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53 52
Preface: Advances in molecular targets for therapeutics in resistant cancers 52
Epidemiology, risk factors, and natural history of hepatocellular carcinoma 52
Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells. 51
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer 51
Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies 51
Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy 51
Extracellular Vesicle-Related Non-Coding RNAs in Hepatocellular Carcinoma: An Overview 51
The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment 51
Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma 50
Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma 50
Nanoparticelle lipidiche solide cationiche come vettori del DNA. 49
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals 49
Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis 49
Lipid nanocarriers containing sorafenib inhibit colonies formation into human hepatocarcinoma cells 49
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals 48
Development of nimesulide loaded solid lipid nanoparticles. 48
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling 47
GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals 47
Emerging Use of Nanotechnology for the Treatment of Liver Diseases 46
Cationic Solid Lipid Nanoparticles as Non Viral Vectors for the Inhibition of Hepatocellular Carcinoma Growth by RNA Interference 46
Synthetic peptide-labelled micelles for active targeting of cells overexpressing EGF receptors 45
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells 45
Expression of HIP/PAP mrna in human hepatoma cell lines 44
Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma 43
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells 43
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. 42
Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53 42
Can Baseline IL-6 Levels Predict Long COVID in Subjects Hospitalized for SARS-CoV-2 Disease? 42
Association Between MICA Gene Variants and the Risk of Hepatitis C Virus-Induced Hepatocellular Cancer in a Sicilian Population Sample 41
Aromatase and amphiregulin are correspondingly espressed in human liver cancer cells. 40
Emerging Raf inhibitors. 40
Non invasive tools for the diagnosis of liver cirrhosis 39
Structure-based identification of a non-covalent thioredoxin reductase inhibitor with proven ADMET suitability 39
Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells 39
Antitumor effects of DHMEQ, a novel NF-kB inhibitor, in human liver cancer cells is mediated through a reactive oxygen species-dependent mechanism. 38
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. 38
Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-±, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma. 38
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. 38
Phosphorylation-dependent regulation of skeletogenesis in sea urchin micromere-derived cells and embryos. 37
Roles of proliferative and metastatic pathways in chemotherapeutic drug resistance and cancer stem cells-sites for therapeutic intervention 37
Effects of ectopic expression of NGAL on doxorubicin sensitivity 37
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. 37
Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression 36
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 35
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells 35
Antitumor effects of curcumin and its combination with cisplatin or doxorubicin on hepatic cancer cells: possible relationship to NF-kB activation and IAP gne expression. 34
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 34
Targeting the cancer initiating cell: The ultimate target for cancer therapy 34
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. 34
From targets to targeted therapies in Hepatocellular carcinoma 34
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells. 34
Molecular mechanisms of sorafenib action in liver cancer cells. 34
Cationic solid-lipid nanoparticles for gene delivery. 34
GDF11 induces mild hepatic fibrosis independent of metabolic health 33
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 33
Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies 33
Cyclooxygenases in cancer 33
Totale 5.514
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.537
article - articoli 23.365
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 684
Totale 55.586
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202422 0 0 0 0 0 0 0 0 1 0 13 8
2024/20253.347 38 26 243 138 658 141 44 144 84 261 867 703
2025/20265.426 282 485 505 956 945 166 724 348 308 291 240 176
2026/2027283 262 21 0 0 0 0 0 0 0 0 0 0
Totale 9.078